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Abstract In order to elucidate molecular events in BCR/ABL-
induced transformation, we adopted a polymerase chain reaction
(PCR)-based technique of differential display and compared
mRNA expression in human factor-dependent cells, TF-1, with
that in factor-independent cells, ID-1, which were established
from TF-1 cells by transfection of BCR/ABL. Cloning and
sequencing of a gene which was upregulated in ID-1 cells revealed
that the gene was identical to a melanoma antigen, PRAME.
Our present study demonstrated that PRAME was markedly
expressed in primary leukemic cells with chronic myeloid
leukemia (CML) in blastic crisis and Philadelphia (Ph)+-acute
lymphoblastic leukemia (ALL), in which BCR/ABL played an
important role as a pathogenic gene. Moreover, comparison of
PRAME expression among CD34+ cells with CML in blastic,
accelerated, and chronic phases revealed a higher expression in
CML in advanced phases. Thus PRAME was considered to be a
good candidate for a marker of Ph+-leukemic blast cells as well
as a new target antigen of leukemic blast cells that cytotoxic T
cells can recognize.
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1. Introduction
BCR/ABL is a fusion gene resulting from Philadelphia (Ph)
chromosome, a hallmark of chronic myeloid leukemia (CML).
It encodes an active tyrosine kinase and plays a crucial role in
the pathogenesis of CML [1]. To isolate genes which are
closely related to BCR/ABL-induced transformation, we
used a di¡erential display approach based on polymerase
chain reaction (PCR) and compared the expression of many
sets of genes between human factor-dependent TF-1 cells [2]
and ID-1 cells which became factor-independent after trans-
fection of TF-1 cells with BCR/ABL [3]. ID-1 cells were less
sensitive to a growth inhibitory e¡ect of interferon-K than
parent TF-1 cells. The basal expression level of IRF-1 and
ISG15 genes, which were known as interferon-K-inducible
genes, was lower in ID-1 cells than parent TF-1 cells [3]. These
results suggested the feasibility of using ID-1 cells as a model
of human CML cells in accelerated or blastic phase and iso-
lating BCR/ABL-inducible genes. In the present study, we
successfully identi¢ed mRNA of a tumor antigen, PRAME,
and also studied expression of PRAME gene in primary leu-
kemic cells.
2. Materials and methods
2.1. Cells
ID-1 was established in our laboratory and reported elsewhere [3].
Brie£y, TF-1 cells [2] were prepared at a concentration of 107 cells/ml
in phosphate-bu¡ered saline (PBS). 10 Wg of pGD210, which was
kindly provided by Dr. George Q. Daley at the Whitehead Institute
for Biomedical Research, was electroporated with a condition of 500
mFD of capacitance and 0.3 V of voltage. The transfected TF-1 cells
were positively selected in 1 mg/ml of G-418 for 7 days and washed
twice with Iscove’s modi¢ed Dulbecco’s medium (IMDM; GIBCO-
BRL, Gaitherburg, MD, USA) containing 10% fetal bovine serum
(FBS) (GIBCO-BRL). The cells were cultured in IMDM supple-
mented with 10% FBS and 5 ng/ml of granulocyte/macrophage col-
ony-stimulating factor (GM-CSF) for 7 days, then split to a single cell
per well and cultured in the same condition. Clones which had been
grown well were selected and a clone was designated as ID-1. ID-1
cells could grow independent of GM-CSF.
2.2. Primary samples
Primary cells or mononuclear cells were obtained from peripheral
blood or aspirated bone marrow cells of normal volunteers and pa-
tients with CML or ALL by density centrifugation using Ficoll-met-
rizoate (Lymphoprep; Nycomed, Oslo, Norway). Microscopically,
more than 80% of nucleated cells were leukemic blast cells in speci-
mens with CML in blastic phase or crisis (CML-BC) and ALL. Clin-
ical stage of CML was classi¢ed into chronic, accelerated, and blastic
phases according to the criteria of international bone marrow trans-
plant registry (IBMTR) [4]. Surface marker analysis of the leukemic
blast cells in CML-BC revealed that they were all positive for CD13,
CD33, and CD34, denoting their myeloid character.
2.3. Separation of CD34-positive progenitor cells from bone marrow of
patients with CML
CD34-positive cells were isolated from bone marrow of patients
with CML by using a MACS system [5] and CD34 progenitor cell
isolation kit (QBEND/10) (Miltenyi Biotec Inc., Sunnyvale, CA,
USA) as recommended by the manufacturer. Brie£y, heparinized
bone marrow cells were incubated with 1:10 (vol/vol) silica (IBL
Co., Fujioka, Japan) at 37‡C for 60 min to remove phagocytic cells
e⁄ciently by density centrifugation. Mononuclear cells were separated
by using Lymphoprep. 108 mononuclear cells were successively incu-
bated for 15 min at 4‡C with a blocking reagent (human IgG) and
mouse monoclonal anti-CD34 antibody followed by washing once
and resuspended. Colloidal superparamagnetic MACS microbeads
recognizing mouse IgG were added, incubated for 15 min at 6‡C.
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Washed cells were then applied onto bu¡er-pre¢lled MiniMACS col-
umn. After the column was washed, enriched CD34-positive cells were
collected. The cells were stained with £uorochromated anti-mouse
reagent and their purity determined £owcytometrically.
2.4. Isolation of total RNA and polyadenylated RNA
Total RNAs were isolated by a modi¢ed acid-guanidine thiocya-
nate-phenol-chloroform method using ISOGEN (Nippon Gene, To-
kyo, Japan) reagents according to the manufacturer’s instructions.
Polyadenylated RNAs were prepared by using FastTrack 2.0 Kit (In-
vitrogen, San Diego, CA, USA) as recommended by the manufac-
turer. RNAs were resuspended in RNase-free water and stored at
380‡C until use.
2.5. Removal of contaminating chromosomal DNA
100 Wg of total RNA was incubated for 60 min at 37‡C with 50
units of human placental ribonuclease inhibitor (GIBCO-BRL), 3 units
of DNase I (Promega, Madison, WI, USA) in 40 mM Tris^Cl, pH
7.4, 0.6 mM MgCl2, 10 mM DTT. After extraction with phenol/
CHCl3/isoamyl alcohol (25:24:1), the supernatant was precipitated
by ethanol in the presence of 0.3 M sodium acetate and RNA was
redissolved in RNase-free water.
2.6. Di¡erential display of mRNAs by PCR [6,7]
Reverse transcription (RT) was performed by incubation of 2.5 Wg
of DNase-treated total RNA at 25‡C for 10 min, 42‡C for 50 min,
and 70‡C for 15 min in a ¢nal volume of 20 Wl with 200 U of Super-
script II (GIBCO-BRL), 10 mM DTT, 1:10 (vol/vol) 10UPCR bu¡er
(GIBCO-BRL preampli¢cation kit), 50 pmol of anchor primer
[G(T)15A] and 0.5 mM of each dNTP (Pharmacia, Piscataway, NJ,
USA). After incubation, RT product was diluted by adding 80 Wl of
TE (10 mM Tris^HCl, pH 8.0, 1 mM EDTA). The PCR was per-
formed by mixing 2 Wl of the diluted RT product to a ¢nal volume of
20 Wl with 0.5 U of a Taq DNA polymerase (GeneTaq) (Nippon
Gene) and 0.5 U of another Taq DNA polymerase (Promega),
0.2 mM dNTP, 0.5 WM of the anchor primer [G(T)15A], 0.5 WM of
an arbitrary primer (AATCGGGCTG) (Operon Technologies, Ala-
meda, CA, USA), and 1:10 (vol/vol) 10UGeneTaq PCR bu¡er (Nip-
pon Gene). The durations and temperatures used were 3 min at 94‡C,
5 min at 40‡C, and 1 min at 72‡C for the initial cycle and 15 s at 94‡C,
2 min at 40‡C, and 1 min at 72‡C for subsequent 25 cycles. 12 Wl of
each PCR product was loaded on a 8% polyacrylamide gel and ana-
lyzed by electrophoresis. The gel was stained by ethidium bromide
staining and di¡erentially expressed bands were identi¢ed. The gel
containing bands which were overexpressed in ID-1 cells were cut
out and washed in distilled water three times. A half of gel slice
was applied into the same PCR solution as above and reampli¢ed
as follows: 3 min at 94‡C and 15 s at 95‡C, 2 min at 40‡C, and
1 min at 72‡C for 20 cycles and 72‡C for 5 min. The PCR products
were electrophoresed. The ampli¢ed band of interest was cut out,
puri¢ed by EASYTRAP (TaKaRa Biomedicals, Shiga, Japan), and
cloned into pCR2.1 by using the TA cloning system (Invitrogen). To
con¢rm that the clone was derived from the band of interest, ECL-
Southern blotting of the initial samples was performed by using the
cloned cDNA probes. Brie£y, 10 Wl of the original samples for di¡er-
ential display from one of which the clone was derived were electro-
phoresed again in a 1% agarose gel, transferred onto Hybond N+
(Amersham Life Science, Buckinghamshire, England), and hybridized
with the cloned DNA probes that were labeled by an ECL system
(Amersham Life Science) as recommended by the manufacturer. Once
the clone was con¢rmed to be of interest, the insert was sequenced by
the dideoxy technique using AutoRead Sequencing Kit (Amersham
Pharmacia Biotech, Tokyo, Japan) and A.L.F. DNA Sequencer II
(Amersham Pharmacia Biotech).
2.7. RT for primary samples
RT was performed by incubation of 1V5 Wg of total RNA derived
from primary samples at 37‡C for 60 min in 20 Wl of ¢nal volume with
200 U of Moloney murine leukemia virus-reverse transcriptase (GIB-
CO-BRL), 10 mM DTT, 1:5 (vol/vol) 5URT bu¡er (GIBCO-BRL),
5 WM of random hexamer [pd(N)6 ; Pharmacia], and 0.5 mM of each
dNTP (Pharmacia).
2.8. PCR for PRAME or L-actin and sample analysis
The PCR was performed by mixing an aliquot of RT product,
which corresponded to 1 Wg total RNA, to a ¢nal volume of 50 Wl
with 1.25 U of Taq DNA polymerase (Promega), 0.25 mM dNTP,
1 WM of 5P sense and 3P antisense primer, 1 mM of MgCl2, and 1:10
(vol/vol) 10UPCR bu¡er (Promega). The mixture was overlaid by
50 Wl of mineral oil and then ampli¢ed for 40 cycles by the Takara
PCR thermal cycler MP (Takara Biomedicals, Osaka, Japan). The
durations and temperatures used in the ¢rst cycle were 30 s at 94‡C
for denaturation, 1 min at 56‡C for annealing, and 2 min at 72‡C for
polymerization. The polymerizing phase was extended 5 s per cycle. In
some experiments, the RT product corresponding to 1 Wg total RNA
was ampli¢ed with primers for PRAME and L-actin mixed together
because Tm of primers were close to each other (Fig. 4B). 10 Wl of the
PCR product was loaded onto 1% agarose gel containing 0.5 Wg/ml of
ethidium bromide and electrophoresed at 100 V for 30 min before
taking picture.
2.9. Primers
Primers used for PCR ampli¢cation and the expected size of prod-
ucts were as follows, in order, (i) 5P sense primer (with the expected
size of PCR product) and (ii) 3P antisense primer. PRAME: (i) 5P-
GCCCAGTTCACCTCTCAGTT-3P (764 bp), (ii) 5P-TGTGGCTGC-
TTTGTTGCTTC-3P, L-actin [8] : (i) 5P-GGCATCGTCACCAACTG-
GGACGAC-3P (878 bp), (ii) 5P-ATTTGCGGTGGACGATGGAGG-
GGC-3P.
3. Results
3.1. Di¡erential display between TF-1 cells and ID-1 cells
Di¡erential display technique using PCR was applied to
¢nd unique genes that were upregulated in ID-1 cells. Com-
parison of gene expression between TF-1 and ID-1 cells by
di¡erential display using more than 20 primer pairs resulted in
identifying several bands which were upregulated in ID-1
cells. Fig. 1 showed a result in which a gene was found to
be overexpressed in ID-1 cells. To exclude a possible contam-
ination of genomic DNA in the original RNA samples, we
treated samples with DNase prior to reverse transcription of
the RNA. Fig. 1A showed no ampli¢cation of bands from
samples without reverse transcription, denoting no contami-
nation of the RNA samples by genomic DNA. Those bands
that were upregulated in ID-1 cells were cloned into pCR2.1
Fig. 1. Electrophoresis of PCR products using an anchor primer
[G(T)15A] and an arbitrary primer (AATCGGGCTG). In order to
deny contamination of genomic DNA, 1.25 Wg of total RNA of a
sample was ampli¢ed without reverse transcription (RT) (A). Note
that no bands were obtained from samples with no RT. A band
which was overexpressed in ID-1 cells was cloned and designated as
HOIMS-1. To con¢rm the clone was derived from the band of in-
terest, ECL-Southern blotting of the initial samples was performed
by using the HOIMS-1 cDNA probes (B).
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at EcoRI site. To con¢rm that a cloned band was the one of
interest, ECL-Southern blotting of the initial RT-PCR prod-
ucts was performed using the cloned sequences as probes. As
shown in Fig. 1B, a gene was con¢rmed to be highly expressed
in ID-1 cells and was temporarily designated as HOIMS-1.
3.2. Genetic analysis of HOIMS-1 gene
Sequencing of HOIMS-1 gene and the initial search for
homology in data banks revealed that it was 99.3% homolo-
gous to an anonymous sequence, HTGS phase 3, complete
sequence (GenBank locus: HSAC000024), 96.7% to testis
2 Homosapiens cDNA clone (T19428), 98.4% to human
HL60 3P directed MboI cDNA (HUMGS 01429), and 100%
to 104 bp of a human erythroleukemic expressed sequence tag
(EST) mRNA fragment (HUMRBCESTC). A couple of
months later, the second computer search for homology re-
vealed that HOIMS-1, which was further sequenced to 1017
bp, was exactly identical to a 3P end of the cDNA of a mel-
anoma antigen, PRAME (Fig. 2) [9]. Northern blotting of
poly(A) RNA of TF-1 and ID-1 cells by using PRAME
cDNA as probes showed marked expression of PRAME
mRNA in ID-1 cells (Fig. 3). These results strongly suggested
that overexpression of BCR/ABL might induce PRAME ex-
pression in ID-1 cells.
3.3. PRAME mRNA expression in primary leukemic cells
RT-PCR analysis of primary leukemic cells demonstrated
that leukemic blast cells from three cases with CML-BC (mye-
loid crisis) and three cases with Ph-positive ALL were all
positive for PRAME mRNA, while bone marrow or periph-
eral mononuclear cells from three cases with chronic phase of
CML (CML-CP), two cases with Ph-negative ALL, and two
healthy volunteers were weakly positive or negative for the
gene (Fig. 4A). Since the blast cells from the patients with
CML-BC were positive for a surface antigen of CD34, which
is characteristic for hematopoietic progenitor cells, the result
of Fig. 4A might re£ect merely quantity of CD34 cells which
might preferentially express PRAME. Thus we analyzed the
mRNA expression of PRAME in CD34-positive blast cells
Fig. 2. PRAME cDNA and HOIMS-1. PRAME cDNA is shown
from 5P to 3P end. HOIMS-1 was revealed to be a 1017 bp fragment
of 3P end of PRAME cDNA as indicated in a rectangle.
Fig. 3. Northern blot analysis of PRAME mRNA in TF-1 and ID-
1 cells. 5 Wg per lane of each poly(A) RNA was analyzed. PRAME
cDNA was used as probe. As RNA loading control, the same blot
was reprobed with L-actin cDNA. Note that PRAME mRNA was
apparently upregulated in ID-1 cells.
Fig. 4. A: Representative data of RT-PCR analysis for PRAME
mRNA expression in human primary leukemic cells and normal
bone marrow mononuclear cells. B: Expression of PRAME mRNA
in primary CD34-positive cells from patients with CML in blastic
crisis (BC), accelerated phase (AP), and chronic phase (CP).
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from CML-BC and CD34-positive bone marrow cells from
the patients with CML in accelerated phase (CML-AP) and
CML-CP by RT-PCR. The purity of CD34-positive cells was
more than 90%. The cells from CML-BC were all positive for
PRAME mRNA by RT-PCR (Fig. 4B). The CD34-positive
cells from a patient with CML-AP, who showed additional
chromosomes, was positive for PRAME. However, cells from
another patient with CML-AP, who had no additional chro-
mosomes but had myelo¢brosis and basophilia, was negative
for PRAME mRNA. The CD34-positive cells from CML-CP
were again all negative for PRAME expression by RT-PCR
(Fig. 4B).
4. Discussion
BCR/ABL is well known as a gene that can transform hem-
atopoietic cells [10] and induce CML in mice [11,12]. Hence
the gene is believed to be crucial in the pathogenesis of CML
and Ph-positive ALL. Knowing e¡ectors downstream of
BCR/ABL in signal transduction of the a¡ected cells is useful
to develop a new strategy to control the leukemic cells of
CML and Ph-positive ALL. As BCR-ABL-inducible genes,
kir/gem was reported although its function remains to be
clari¢ed [13]. In the present study, we performed a PCR-based
di¡erential display approach to identify a new BCR/ABL-in-
ducible gene and compared sets of genes expressed between
parent TF-1 cells and ID-1 cells that were BCR/ABL cDNA
transformed, factor-independent, and interferon-K-resistant
TF-1 cells. In our experiments, we modi¢ed original methods
to use non-denaturing gels to avoid the complexity of the
patterns obtained in the denaturing polyacrylamide gels ac-
companied with the several bands derived from one DNA
species. Moreover, we visualized PCR-ampli¢ed bands by
ethidium bromide staining, instead of using isotopes or £uo-
rescence, to obtain genes with increased level of mRNA com-
pared with other genes, avoiding too many meaningless bands
which hindered further analysis. Many genes were di¡eren-
tially expressed between TF-1 and ID-1 cells even with our
method. Among them a gene which was apparently overex-
pressed in ID-1 cells was designated as HOIMS-1 and ana-
lyzed in this study. Cloning and sequencing showed that
HOIMS-1 had a high homology with several genes reported
in GenBank.
Ikeda et al. reported a gene, PRAME, encoding a melano-
ma tumor antigen [9]. PRAME-encoding antigen was recog-
nized by cytotoxic T lymphocytes (CTL) in a HLA-24-re-
stricted manner. The gene was expressed ubiquitously in
normal human tissues at a low level and highly expressed in
testis. PRAME was also expressed in many neoplastic tumors
including melanoma, lung cancer, renal cancer, and acute leu-
kemia [9]. In the present study, we showed that HOIMS-1 was
a PRAME gene and a candidate BCR/ABL-inducible gene.
The character of ID-1 was reported to be close to that of
leukemic blasts in CML-BC [3]. The results of RT-PCR for
PRAME mRNA expression using primary leukemic cells sup-
ported this hypothesis. All the cases of CML-BC and Ph-pos-
itive ALL tested were positive for PRAME mRNA although
other cases including CML-CP and Ph-negative ALL were
only weakly positive or negative. Generally leukemic blast
cells of CML-BC and Ph-positive ALL are positive for
CD34, rising the possibility that expression of PRAME is
increased in CD34-positive populations in the leukemic cells.
Therefore we compared PRAME mRNA expression levels in
CD34-positive cells with di¡erent clinical stages of CML. As
shown in Fig. 4B, a high level of PRAME mRNA expression
was not ubiquitous in CD34-positive cells, but seemed to be
marked in leukemic blast cells of CML-BC in myeloid crisis.
In fact, CD34-positive cells from a male patient with CML-
AP with a cytogenetic clonal evolution, implying that his clin-
ical feature was close to CML-BC, were positive for PRAME,
but the cells from another patient with CML-AP without any
cytogenetic change were negative for PRAME. These results
did not show that the mRNA was absent in the cells with
CML-AP or CP since the level of PRAME mRNA expression
could be low and merely under the sensitivity of PCR in those
cells. However, the results suggested that the level of PRAME
expression was increased in the leukemic blasts with CML-
BC, re£ected the acceleration of CML, and was useful to
diagnose the clinical stage of CML.
Anti-leukemia immunotherapy has been extensively investi-
gated and clinically practiced. However, few tumor antigens,
which could be speci¢cally recognized by CTL, have been
identi¢ed in leukemia. PRAME was reported to be expressed
in various types of acute leukemia, especially in acute myeloid
leukemia with a speci¢c karyotype of t (8;21), which generates
a fusion gene of AML-1/ETO [14]. It is interesting to note
that the report and our results suggested that AML1/ETO
might share its signal transduction pathway with BCR/ABL.
AML with t (8;21) is a representative of leukemia with a good
prognosis while CML-BC and Ph-positive ALL are well
known as leukemias with very poor prognosis. In the AML
patients with t (8;21), PRAME might be recognized as tumor
speci¢c antigen by CTL. Whether CTL activity against
PRAME-positive leukemic cells is higher in AML patients
with AML-1/ETO than CML patients with BCR/ABL re-
quires further investigation. As mentioned above, PRAME
mRNA expression was not restricted to leukemia, but distrib-
uted to various types of malignant tumors [9]. Hence develop-
ment of CTL which recognizes PRAME could be useful and
applicable for the treatment of various neoplasms as well as
leukemia.
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